S&P ASX All Technology

3,629.80

-3.15%

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

MYNZ

Mainz BioMed NV (MYNZ)

Mainz BioMed NV

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MYNZ

1 2 3 4 5 6 7 Next >>

Date	Time	Source	Headline	Symbol	Company
04/03/2025	00:01	GlobeNewswire Inc.	Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention	NASDAQ:MYNZ	Mainz BioMed NV
21/02/2025	00:01	GlobeNewswire Inc.	Mainz Biomed Expands into Switzerland with labor team w	NASDAQ:MYNZ	Mainz BioMed NV
12/02/2025	00:01	GlobeNewswire Inc.	Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month	NASDAQ:MYNZ	Mainz BioMed NV
28/01/2025	00:01	GlobeNewswire Inc.	Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements	NASDAQ:MYNZ	Mainz BioMed NV
28/01/2025	00:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
22/01/2025	00:01	GlobeNewswire Inc.	Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population	NASDAQ:MYNZ	Mainz BioMed NV
15/01/2025	09:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
20/12/2024	00:01	GlobeNewswire Inc.	Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test	NASDAQ:MYNZ	Mainz BioMed NV
17/12/2024	09:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
17/12/2024	09:00	GlobeNewswire Inc.	Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering	NASDAQ:MYNZ	Mainz BioMed NV
17/12/2024	00:00	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:MYNZ	Mainz BioMed NV
14/12/2024	00:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
13/12/2024	16:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:MYNZ	Mainz BioMed NV
13/12/2024	12:00	GlobeNewswire Inc.	Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules	NASDAQ:MYNZ	Mainz BioMed NV
12/12/2024	01:22	InvestorsHub NewsWire	Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN	NASDAQ:MYNZ	Mainz BioMed NV
12/12/2024	00:00	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:MYNZ	Mainz BioMed NV
10/12/2024	09:11	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:MYNZ	Mainz BioMed NV
10/12/2024	01:16	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:MYNZ	Mainz BioMed NV
30/11/2024	00:45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
30/11/2024	00:45	GlobeNewswire Inc.	Mainz Biomed Announces Stock Split	NASDAQ:MYNZ	Mainz BioMed NV
16/11/2024	09:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
13/11/2024	01:09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
13/11/2024	01:00	GlobeNewswire Inc.	Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets	NASDAQ:MYNZ	Mainz BioMed NV
06/11/2024	00:00	Edgar (US Regulatory)	Form F-1 - Registration statement for certain foreign private issuers	NASDAQ:MYNZ	Mainz BioMed NV
21/10/2024	23:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
21/10/2024	23:01	GlobeNewswire Inc.	Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update	NASDAQ:MYNZ	Mainz BioMed NV
19/10/2024	07:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
10/10/2024	08:20	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV
08/10/2024	23:01	GlobeNewswire Inc.	Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version	NASDAQ:MYNZ	Mainz BioMed NV
04/10/2024	07:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MYNZ	Mainz BioMed NV